2 results
Approved WMORecruiting
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.
Approved WMOCompleted
Primary Objective:• To assess and compare efficacy of sacituzumab govitecan to TPC as measured by progression free survival (PFS) as determined by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1…